Pharmaceuticals, Biotechnology and Life Sciences
SYDNEY, Australia, June 06, 2024 (GLOBE NEWSWIRE) — EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 06, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)…
BOSTON and SAN DIEGO, June 06, 2024 (GLOBE NEWSWIRE) — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused…
WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), is a…
REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that…
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall…
In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved…
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and…
An additional 19 patients have been enrolled since January 2024 bringing the total to 37 of whom 25 were evaluable for…
Media Release COPENHAGEN, Denmark, and MAINZ, Germany; June 1, 2024 Initial data from the ongoing Phase 2 trial showed a…